RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 1167-1172

  Wang, Gang Zhi ^a,b   Fukazawa, Takuya ^b   Nishikawa, Toshio ^b   Watanabe, Nobuyuki ^b   Sakurama, Kazufumi ^b   Motoki, Takayuki ^b   Hatakeyama, Shinji ^c   Omori, Osamu ^c   Ohara, Toshiaki ^b   Tanabe, Shunsuke ^b   Fujiwara, Yasuhiro ^b   Takaoka, Munenori ^b   Shirakawa, Yasuhiro ^b   Yamatsuji, Tomoki ^b   Tanaka, Noriaki ^b   Naomoto, Yoshio ^b  

^a INNER MONGOLIA UNIVERSITY   (China)

^b OKAYAMA UNIVERSITY   (Japan)

^c Novarutis Pharma   (Japan)

Author keywords

Cell growth; Esophageal cancer cells; mTOR signaling; RAD001 (everolimus)

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; S6 KINASE;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DAMAGE; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EPITHELIUM CELL; ESOPHAGUS CANCER; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RIBOSOMAL PROTEIN S6 KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 77949435090     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000747     Document Type: Article

References (48)

1. Lambert R and Hainaut P: Esophageal cancer: cases and causes (Part I). Endoscopy 39: 550-555, 2007.
2. Lambert R and Hainaut P: Esophageal cancer: the precursors (Part II). Endoscopy 39: 659-664, 2007.
3. Wu X, Chen VW, Andrews PA, Ruiz B and Correa P: Incidence of esophageal and gastric cancer among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control 18: 585-593, 2007.
4. Wu X, Chen VW, Ruiz B, Andrews P, Su LJ and Correa P: Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, Whites, and Blacks: subsite and histology differences. Cancer 106: 683-692, 2006.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
6. Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, Negri E and Vecchia CL: Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 122: 1118-1129, 2008.
7. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
8. Wan X and Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist 12: 1007-1018, 2007.
9. Hou G, Xue L, Lu Z, Fan T, Tian F and Xue Y: An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett 253: 236-248, 2007.
10. Tsang CK, Qi H, Liu LF and Zheng XFS: Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12: 112-124, 2007.
11. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX and Rassidakis GZ: Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66: 6589-6597, 2006.
12. Sahin F, Kannangai R, Adegbola O, Wang J, Su G and Torbenson M: mTOR and p70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10: 8421-8425, 2004.
13. Jiang H, Coleman J, Miskimins R and Miskimins WK: Expression of constitutively active 4EBP-I enhances p27Kip I expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int 3: 2, 2003.
14. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC and Testa JR: RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67: 2408-2413, 2007.
15. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ and Koeffler HP: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21: 333-339, 2007.
16. Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005.
17. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G and Lane HA: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64: 252-261, 2004.
18. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S, Lietz A and Dorken B: A rapamycin derivative (everolimus) controls proliferation though down-regulation of truncated CCAAT enhancer binding protein and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood 106: 1801-1807, 2005.
19. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HHD and Auernhammer CJ: The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85: 54-60, 2007.
20. Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C and Decker T: Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitizes DLBCL cells to rituximab. Br J Haematol 134: 474-484, 2006.
21. Ferri N, Granata A, Pirola C, Torti F, Pfister PJ, Dorent R and Corsini A: Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. Mol Pharmacol 74: 144-153, 2008.
22. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA and Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120: 747-759, 2005.
23. Sarkar FH and Li Y: Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol Sin 28: 1305-1315, 2007.
24. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S and Lane HA: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11: 5319-5328, 2005.
25. Wu L, Birle DC and Tannock IF: Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65: 2825-2831, 2005.
26. Panwalkar A, Verstovsek S and Giles FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100: 657-666, 2004.
27. Albert JM, Kim KW, Cao C and Lu B: Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 5: 1183-1189, 2006.
28. Cao C, Subhawong T, Albert JM, Kim KW Geng L, Sekhar KR, Gi YJ and Lu B: Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66: 10040-10047, 2006.
29. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF and Testa JR: RAD001 inhibits human cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an cancer model. Clin Cancer Res 13: 4261-4270, 2007.
30. Goudar RK, Shi Q, Hielmeland MD, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS and Rich JN: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4: 101-112, 2005.
31. Homicsko K, Lukashev A and Iggo RD: RAD001 (Everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 65: 6882-6890, 2005.
32. Yee KWL, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M and Giles FJ: PhaseI/II study of the Mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12: 5165-5173, 2006.
33. Schmelzle T and Hall MN: TOR, a central controller of cell growth. Cell 103: 253-262, 2000.
34. Wang ZG, Wu YJ and Shorgen: The mTOR signaling pathway and the regulation of cell growth. (in Chinese) Acta Biophysica Sinaca 22: 333-342, 2007.
35. Albanell J, Dalmases A, Rovira A and Rojo F: mTOR signaling in human cancer. Clin Transl Oncol 9: 484-493, 2007.
36. Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000.
37. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006.
38. Shaw RJ and Cantley LC: Ras, PI3K and mTOR signaling controls tumour cell growth. Nature 441: 424-430, 2006.
39. Shah OJ and Hunter T: Turnover of the active fraction of IRS1 involves raptor-mTOR and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol 26: 6425-6434, 2006.
40. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J and Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006.
41. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007.
42. Shi Y, Yan H, Frost P, Gera J and Lichtenstein A: Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like groth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 4: 1533-1540, 2005.
43. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H and Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058, 2005.
44. Failly M, Korur S, Egler V, Boulay JL, Lino MM, Imber R and Merlo A: Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol Cancer Ther 6: 773-781, 2007.
45. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP and Taguchi H: The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 5: 2522-2530, 2006.
46. Kim KW, Mutter RW, Cao C, Albert JM, Freeman MF, Hallahan DE and Lu B: Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Bio Chem 281: 36883-36890, 2006.
47. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y and Jiang Y: Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318: 977-980, 2007.
48. Proud CG: mTOR, unleashed. Science 318: 926-927, 2007.